aTyr Pharma (NASDAQ:LIFE) was upgraded by Citigroup from a “sell” rating to a “neutral” rating in a research report issued on Thursday, MarketBeat Ratings reports. The brokerage currently has a $0.75 price objective on the biotechnology company’s stock, down from their previous price objective of $1.00. Citigroup’s price target points to a potential upside of 15.38% from the stock’s previous close.

LIFE has been the topic of several other research reports. ValuEngine raised shares of aTyr Pharma from a “strong sell” rating to a “sell” rating in a research note on Wednesday, May 2nd. BMO Capital Markets reduced their price target on shares of aTyr Pharma from $2.00 to $1.00 and set a “hold” rating on the stock in a research note on Wednesday. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $3.00 price target on shares of aTyr Pharma in a research note on Monday, May 14th. Finally, Zacks Investment Research downgraded shares of aTyr Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, July 17th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $1.94.

LIFE stock opened at $0.65 on Thursday. The stock has a market capitalization of $20.50 million, a P/E ratio of -0.35 and a beta of 3.03. aTyr Pharma has a 12 month low of $0.60 and a 12 month high of $6.50. The company has a current ratio of 6.90, a quick ratio of 6.90 and a debt-to-equity ratio of 0.24.

aTyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings results on Tuesday, August 14th. The biotechnology company reported ($0.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.01). equities research analysts expect that aTyr Pharma will post -1.28 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of LIFE. Sofinnova Ventures Inc purchased a new position in aTyr Pharma during the 1st quarter valued at about $4,945,000. Renaissance Technologies LLC increased its position in aTyr Pharma by 143.2% during the 4th quarter. Renaissance Technologies LLC now owns 279,400 shares of the biotechnology company’s stock valued at $978,000 after purchasing an additional 164,500 shares during the period. Deutsche Bank AG purchased a new position in aTyr Pharma during the 4th quarter valued at about $199,000. Finally, Dimensional Fund Advisors LP increased its position in aTyr Pharma by 33.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 114,449 shares of the biotechnology company’s stock valued at $303,000 after purchasing an additional 28,699 shares during the period. 64.53% of the stock is currently owned by institutional investors and hedge funds.

About aTyr Pharma

aTyr Pharma, Inc, a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.

See Also: Penny Stocks

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.